Search results for "Anesthesia"

showing 10 items of 2277 documents

Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study.

2014

Abstract Introduction Epistaxis is the most frequent manifestation in hereditary hemorrhagic telangiectasia, in which no optimal treatment exists. It can lead to severe anemia and reduced quality of life. Positive effects of tranexamic acid, an antifibrinolytic drug, have been reported on epistaxis related to this disorder. We sought to evaluate the efficacy of treating nosebleeds in hereditary hemorrhagic telangiectasia with tranexamic acid. Materials and Methods In a randomized, double-blind, placebo controlled, cross-over phase IIIB study, 1 gram of tranexamic acid or placebo was given orally 3 times daily for 3 months for a total of 6 months. Results 22 patients were included in the int…

AdultMaleAntifibrinolyticTime Factorsmedicine.drug_classMedizinAdministration OralPlaceboDrug Administration ScheduleDouble blindQuality of lifeDouble-Blind MethodGermanymedicineHumansTelangiectasiaAgedDiminutionCross-Over Studiesbusiness.industryHematologyMiddle AgedAntifibrinolytic AgentsClinical trialEpistaxisTreatment OutcomeTranexamic AcidAnesthesiaFemaleTelangiectasia Hereditary Hemorrhagicmedicine.symptombusinessTranexamic acidmedicine.drugThrombosis research
researchProduct

Absence of cardiovascular autonomic dysfunction and vagal pancreatic impairment in idiopathic achalasia of the oesophagus

2007

Abstract  Extra-oesophageal autonomic dysfunction in idiopathic achalasia is not well documented, due to contradictory results reported. We aimed to study the cardiovascular and pancreatic autonomic function in patients with idiopathic achalasia. Thirty patients with idiopathic achalasia (16M/14F; 34.5 ± 10.8 years) and 30 healthy volunteers (13M/17F; 34.8 ± 10.7 years) were prospectively studied. Age >60 years and conditions affecting results of autonomic evaluation were excluded. Both groups underwent the sham feeding test and plasmatic levels of pancreatic polypeptide (PP) were determined by radioimmunoassay (basal, at 5, 10, 20 and 30 min). Cardiovascular parasympathetic (deep breathing…

AdultMaleAutonomic functionmedicine.medical_specialtyAdolescentPhysiologyDiaphragmatic breathingAchalasiaAutonomic Nervous SystemPancreatic PolypeptideEatingEsophagusInternal medicinemedicineHumansPancreatic polypeptideEndocrine and Autonomic Systemsbusiness.industryGastroenterologyVagus NerveRadioimmunoassayMiddle Agedmedicine.diseaseSham feedingEsophageal AchalasiaBlood pressureTasteAnesthesiaCardiologyMasticationFemaleIdiopathic achalasiabusinessNeurogastroenterology & Motility
researchProduct

Central correlation of muscle sympathetic nerve activation during baroreflex unloading - a microneurography-positron emission tomography study

2013

The baroreceptor reflex controls spontaneous fluctuations in blood pressure. One major control variable of the baroreflex is the sympathetic vasoconstrictor activity to muscles [MSNA; burst frequency (BF) and burst incidence (BI)], which can be quantitatively assessed by microneurography. We aimed to investigate the central regions involved in baroreflex regulation of MSNA. Healthy men (mean age 25 years) participated in three experimental sessions. (i) Microneurography recordings of MSNA from the left peroneal nerve during rest and baroreflex unloading, induced by lower body negative pressure (LBNP; -40 mmHg). If MSNA could be reliably recorded throughout this procedure (n = 15), the subje…

AdultMaleBaroreceptorbusiness.industryGeneral NeuroscienceBrainPeroneal NerveRostral ventrolateral medullaMicroneurographyBaroreflexBaroreflexGlucoseBlood pressureOrgan SpecificityPositron-Emission TomographyAnesthesiaMedulla oblongataHumansMedicineBrainstemMuscle SkeletalbusinessMedullaEuropean Journal of Neuroscience
researchProduct

TNF-α in CRPS and 'normal' trauma--significant differences between tissue and serum.

2011

Posttraumatic TNF-alpha signaling may be one of the factors responsible for pain and hyperalgesia in complex regional pain syndromes (CRPS). In order to further specify the role of TNF-alpha we investigated tissue (skin) and serum concentrations in three different patient groups: patients with osteoarthritis and planned surgery, with acute traumatic upper limb bone fracture waiting for surgery, and with CRPS I. Thirty patients (10 in each group) were recruited. Mean CRPS duration was 36.1 ± 8.1 weeks (range 8- 90 weeks). Skin punch biopsies were taken at the beginning of the surgery in osteoarthritis and fracture patients and from the affected side in CRPS patients. Blood samples were taken…

AdultMaleBone pathologyEnzyme-Linked Immunosorbent AssayPilot ProjectsOsteoarthritisFractures BoneOsteoarthritismedicineHumansAgedSkinAged 80 and overmedicine.diagnostic_testbusiness.industryTumor Necrosis Factor-alphaBone fractureMiddle Agedmedicine.diseaseUp-RegulationAnesthesiology and Pain Medicinemedicine.anatomical_structureComplex regional pain syndromeNeurologyAnesthesiaSkin biopsyHyperalgesiaAcute DiseaseUpper limbWounds and InjuriesTumor necrosis factor alphaFemaleNeurology (clinical)medicine.symptombusinessComplex Regional Pain SyndromesPainReferences
researchProduct

Scalp, earlobe and nasopharyngeal recordings of the median nerve somatosensory evoked P14 potential in coma and brain death

1996

Median nerve somatosensory evoked potentials (SEPs) were recorded in a total of 181 patients in coma and brain death. Special attention was paid to derivation of P14 (the positive potential occurring approximately 14 ms after median nerve stimulation) with different electrode montages, using midfrontal scalp (Fz), linked earlobe (A1/2), median nasopharyngeal (Pgz) and non-cephalic reference (NC) electrodes. The P14 amplitude (and, to a lesser extent, latency) were invariably lower in brain death than in coma. The potential was preserved in coma in all patients, but lost in brain death in 9.8% in Fz-NC and Pgz-NC recordings, in 23.2% in Fz-A1/2, and in 100% in Fz-Pgz. Thus, Fz-Pgz was the de…

AdultMaleBrain DeathAdolescentNeurological disorderSomatosensory systemLesionEvoked Potentials SomatosensoryReaction TimemedicineHumansComaChildEarlobeAgedAged 80 and overComaMiddle Agedmedicine.diseaseMedian nerveMedian Nervemedicine.anatomical_structureSomatosensory evoked potentialScalpAnesthesiaFemaleNeurology (clinical)medicine.symptomPsychologyBrain
researchProduct

Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain d…

2011

Abstract Context Cancer patients receiving high doses of opioids as background medication are challenging, and it would be useful clinically to know whether a rapid-onset opioid (ROO) for breakthrough cancer pain (BTcP) may be started at a dose proportional to the background opioid dose. Objectives The aim of this study was to assess the efficacy and safety of the fentanyl buccal tablet (FBT) in doses proportional to the opioid dose administered for background analgesia in a sample of patients with BTcP who were receiving high doses of opioids. Methods Twelve patients who were receiving opioids for background analgesia at doses equivalent to more than 500 mg of oral morphine and had adequat…

AdultMaleBreakthrough PainContext (language use)Settore MED/42 - Igiene Generale E ApplicataFentanylNeoplasmsHumansMedicineAdverse effectGeneral NursingAgedPain MeasurementDose-Response Relationship Drugbusiness.industryBreakthrough PainAdministration BuccalCancerclinical trialBuccal administrationMiddle Agedmedicine.diseaseFentanyl buccal tabletbreakthrough pain cancer patientAnalgesics OpioidFentanylTreatment OutcomeAnesthesiology and Pain MedicineOpioidAnesthesiaFemaleNeurology (clinical)businessCancer painmedicine.drug
researchProduct

The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing

2004

Budesonide/formoterol in a single inhaler is an effective therapy for asthma. We investigated whether adjustable maintenance dosing with budesonide/formoterol could maintain health-related quality of life (HRQL) and asthma control.Asthma patients (n = 4025) received budesonide/formoterol (Symbicort 160/4.5 microg) 2 inhalations twice daily (b.i.d.) for 4 weeks during run-in of this open, multicentre study. Patients were randomised to adjustable dosing (budesonide/formoterol 1 inhalation b.i.d.; stepping up to 2 or 4 inhalations bid for 1 week if asthma worsened) or fixed dosing (budesonide/formoterol 2 inhalations b.i.d.), for 12 weeks. Change in HRQL (standardised Asthma Quality of Life Qu…

AdultMaleBudesonideAdolescentDrug Administration Scheduleimmune system diseasesFormoterol FumarateAdministration InhalationmedicineHumansAnti-Asthmatic AgentsMetered Dose InhalersDosingBudesonideAgedAsthmaInhalationbusiness.industryInhalerGeneral MedicineMiddle Agedmedicine.diseaseAsthmaRespiratory Function Testsrespiratory tract diseasesDrug CombinationsTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaQuality of LifeFemaleFormoterol FumarateFormoterolbusinessmedicine.drugCurrent Medical Research and Opinion
researchProduct

Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study

2012

SummaryBackgroundStudies with inhaled corticosteroids (ICS) in smoking asthmatics have mostly shown poorer treatment responses than in non-smoking asthmatics.MethodsEuroSMART, an open, randomised, 6-month study, compared budesonide/formoterol (Symbicort ® Turbuhaler®)hhNeither the Symbicort SMART posology nor the dry powder formulation, Turbuhaler, is currently approved in the US. maintenance and reliever therapy (Symbicort SMART®) at two maintenance doses of budesonide/formoterol (160/4.5 μg), 1 × 2 and 2 × 2, in patients with asthma who were symptomatic despite treatment with ICS ± long-acting β2-agonists. The 8424 randomised patients included 886 smokers (11%; aged <40 years or with a sm…

AdultMaleBudesonidePulmonary and Respiratory MedicineSymbicort SMARTmedicine.medical_specialtyPeak Expiratory Flow RatePropensity-matched controlsDrug Administration Schedulelaw.inventionACQ-5Budesonide/formoterol maintenance and reliever therapyPharmacotherapyRandomized controlled triallawFormoterol FumarateSurveys and QuestionnairesInternal medicineAdministration InhalationmedicineHumansAnti-Asthmatic AgentsDosingBudesonideAsthmaSmokersDose-Response Relationship Drugbusiness.industrySmokingmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaDisease ProgressionDrug Therapy CombinationFemaleFormoterol FumarateFormoterolbusinessmedicine.drugRespiratory Medicine
researchProduct

The use of esmolol in whole-body hyperthermia: Cardiovascular effects

1997

Whole-body hyperthermia (WBH) is a well-described investigational adjunct to systemic chemotherapy for the treatment of advanced malignancies. The hemodynamic consequences of this physiologic state may include tachycardia, which can produce acute myocardial ischemia in patients with coronary artery disease. Ischemic heart disease is currently considered a contraindication to WBH. We chose to investigate the consequences of using a new beta 1-adrenergic antagonist, esmolol, to attempt to control the tachycardia associated with WBH. After institutional approval and patient consent, nine consecutive patients with normal cardiac function presenting for WBH with carboplatin infusion were studied…

AdultMaleCancer ResearchMean arterial pressureCardiac outputHeart diseasePhysiologySinus tachycardiaAdrenergic beta-AntagonistsCardiac indexAntineoplastic AgentsCoronary DiseaseCarboplatinPropanolaminesHeart RateNeoplasmsTachycardiaPhysiology (medical)Heart rateHumansMedicineInfusions Intravenousbusiness.industryContraindicationsHemodynamicsHyperthermia InducedMiddle Agedmedicine.diseaseEsmololCombined Modality TherapyAnesthesiaHeart failureFemaleSafetymedicine.symptombusinessmedicine.drugInternational Journal of Hyperthermia
researchProduct

Role of ondansetron plus dexamethasone in fractionated chemotherapy.

1993

This randomised, double-blind, parallel-group study was carried out to compare the efficacy and safety profile of ondansetron plus dexamethasone and metoclopramide plus dexamethasone in patients receiving fractionated cisplatin (20-25 mg/m2/day) chemotherapy for the treatment of testicular cancer. An interim analysis of 95 patients showed that the ondansetron regimen was significantly superior compared to the metoclopramide regimen (p0.001). According to the study protocol the study was terminated at this stage. At the time the decision to stop the study was taken, a total of 113 patients had been enrolled and were evaluable on an 'intention to treat' basis. Fifty-six of these had received …

AdultMaleCancer ResearchMetoclopramideAdolescentMetoclopramideVomitingmedicine.medical_treatmentDexamethasoneDrug Administration ScheduleOndansetronTesticular NeoplasmsMedicineHumansIn patientDexamethasoneAgedChemotherapybusiness.industryNauseaGeneral MedicineMiddle AgedOndansetronSafety profileOncologyAnesthesiaCisplatinbusinessmedicine.drugOncology
researchProduct